Kitanaka J, Kitanaka N, Tatsuta T, Morita Y, Takemura M
Department of Pharmacology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Neuroscience. 2007 Jul 13;147(3):765-77. doi: 10.1016/j.neuroscience.2007.05.006. Epub 2007 Jun 14.
The administration of methamphetamine (METH, 10 mg/kg, i.p.) to male ICR mice induced stereotyped behavior consisting of nail and/or wood chip biting (86.0%), continuous sniffing (12.0%), head bobbing (1.1%), and circling (1.0%) during the observation period of 1 h. Pretreatment of the mice with metoprine (2, 10, and 20 mg/kg, i.p.), a selective inhibitor of histamine N-methyltransferase (HMT), which metabolizes histamine in the brain, significantly increased and decreased METH-induced continuous sniffing (20.5, 51.3, and 80.3%) and nail and/or wood chip biting (77.4, 45.3, and 14.2%), respectively, in a dose-dependent manner. The hypothalamic contents of histamine and its metabolite N(tau)-methylhistamine were significantly increased and decreased by metoprine (10 mg/kg, i.p.), respectively. The metoprine action on METH-induced behavior was completely abolished by pyrilamine (10 and 20 mg/kg) and ketotifen (10 mg/kg), selective, centrally acting histamine H(1) receptor antagonists, but not by fexofenadine (20 mg/kg), zolantidine (10 mg/kg) and thioperamide (10 mg/kg), a peripherally acting histamine H(1) receptor antagonist and a selective, brain-penetrating antagonist for histamine H(2) and H(3) receptors, respectively. The metoprine action was mimicked by SKF 91488 (100 microg/animal, i.c.v.), another HMT inhibitor, and the action of SKF 91488 was also blocked by pyrilamine. The frequency of the expression of METH-induced total stereotypic patterns was unchanged after metoprine pretreatment. Mice pretreated with metoprine displayed no anxiety-like behavior in the elevated plus maze test. These results suggest that brain histamine, increased by agents such as metoprine and SKF 91488, binds to histamine H(1) receptors in the brain, resulting in the modulation of dopaminergic transmission associated with stereotyped behavioral patterns induced by METH.
给雄性ICR小鼠腹腔注射甲基苯丙胺(METH,10毫克/千克),在1小时的观察期内诱发了刻板行为,包括咬指甲和/或木屑(86.0%)、持续嗅探(12.0%)、点头(1.1%)和转圈(1.0%)。用美托普林(2、10和20毫克/千克,腹腔注射)对小鼠进行预处理,美托普林是组胺N-甲基转移酶(HMT)的选择性抑制剂,可代谢大脑中的组胺,结果以剂量依赖的方式显著增加和减少了METH诱导的持续嗅探(分别为20.5%、51.3%和80.3%)以及咬指甲和/或木屑(分别为77.4%、45.3%和14.2%)。美托普林(10毫克/千克,腹腔注射)分别显著增加和减少了下丘脑组胺及其代谢物N(τ)-甲基组胺的含量。美托普林对METH诱导行为的作用被选择性中枢作用的组胺H(1)受体拮抗剂吡苄明(10和20毫克/千克)和酮替芬(10毫克/千克)完全消除,但未被外周作用的组胺H(1)受体拮抗剂非索非那定(20毫克/千克)、佐兰替丁(10毫克/千克)和硫代酰胺(10毫克/千克)消除,硫代酰胺分别是组胺H(2)和H(3)受体的选择性脑穿透拮抗剂。美托普林的作用被另一种HMT抑制剂SKF 91488(100微克/动物,脑室内注射)模拟,且SKF 91488的作用也被吡苄明阻断。美托普林预处理后,METH诱导的总刻板模式的表达频率未改变。用美托普林预处理的小鼠在高架十字迷宫试验中未表现出焦虑样行为。这些结果表明,美托普林和SKF 91488等药物增加的脑组胺与大脑中的组胺H(1)受体结合,导致与METH诱导的刻板行为模式相关的多巴胺能传递受到调节。